echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Positive results were obtained in the clinical trial of dkn-01 combined with keytruda in the treatment of gastric cancer

    Positive results were obtained in the clinical trial of dkn-01 combined with keytruda in the treatment of gastric cancer

    • Last Update: 2019-08-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today, leap therapeutics announced that its antagonist dkn-01 targeting the new target DKK1, in combination with keytruda, has obtained positive results in clinical trials (http://www.chemdrug.com/sell/24/) for the treatment of DKK1 overexpression in patients with advanced gastric esophageal junction adenocarcinoma / gastric cancer Dkn-01 dkn-01 is a humanized monoclonal antibody against DKK1 protein DKK1 is a protein that regulates Wnt signaling pathway and is highly expressed in many tumors DKK1 can help maintain tumor microenvironment with immunosuppressive effect around tumor This clinical trial included dkn-01 as a single therapy and a multi part study in combination with paclitaxel or keytruda Among them, 63 patients received dkn-01 combined with keytruda Of these patients, 53 had not previously received PD-1 / PD-L1 inhibitors, and 10 were resistant to PD-1 / PD-L1 inhibitors All the patients in the group were microsatellite stable or unknown All patients in this study have received one to five different treatments The results showed that the combination of dkn-01 and keytruda could improve the prognosis of patients with DKK1 overexpression of PD-1 / PD-L1 inhibitors In 10 evaluable DKK1 overexpression patients, the treatment achieved a median progression free survival (PFS) of more than 22 weeks and a median overall survival (OS) of nearly 32 weeks, as well as a 50% overall response rate (ORR) and 80% disease control rate (DCR) The mean PFS was 6 weeks, OS was more than 17 weeks, and DCR was 20% in 15 evaluable DKK1 low expression patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.